Abstract: Provided is an application of tranilast in the preparation of a medicament for treating scleredema diabeticorum. Tranilast was originally used clinically for the treatment of allergic diseases and keloids, which is a safe and effective medicament with few adverse reactions that has been used clinically for many years, it is currently used in patients with scleredema diabeticorum who have no definite therapeutic schedule, and after 3 months of application, the symptoms may be observed to be significantly relieved in clinical practice, the thickness of the skin was significantly thinner detected by B-ultrasound and no significant adverse reactions were observed. This suggests that the medicament can quickly control the skin lesions of the patients with scleredema diabeticorum, reduce the clinical symptoms, and has good tolerance, high patient compliance, rare adverse reactions, and good clinical efficacy and safety.